
Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.
Jennifer Lospinoso is the managing director and consulting lead at Riparian.

Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.

Jennifer Lospinoso explains how cell and gene therapies are reshaping specialty pharmacy commercialization.